Literature DB >> 3160014

Carcinoma of the prostate: remission of paraparesis with inhibitors of bone resorption.

R C Percival, M E Watson, J L Williams, J A Kanis.   

Abstract

We describe a patient with metastatic carcinoma of the prostate associated with paraplegia. The patient also had Paget's disease of bone elsewhere. Because the neurological lesion was thought to be due to Paget's disease, the patient was treated with inhibitors of bone resorption. Treatment rapidly induced clinical remission and inhibition of bone resorption, and withdrawal was associated with relapse. This suggests that such agents may be of value in the treatment of bone disease of prostatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3160014      PMCID: PMC2418436          DOI: 10.1136/pgmj.61.716.551

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  3 in total

1.  Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis?

Authors:  D L Douglas; T Duckworth; J A Kanis; A A Jefferson; T J Martin; R G Russell
Journal:  J Bone Joint Surg Br       Date:  1981

2.  Urinary hydroxyproline excretion in carcinoma of the prostate. A comparison of 4 different modes of assessment and its role as a marker.

Authors:  A R Mundy
Journal:  Br J Urol       Date:  1979-12

3.  The role of mithramycin in the management of Paget's disease.

Authors:  D A Heath
Journal:  Metab Bone Dis Relat Res       Date:  1981
  3 in total
  3 in total

1.  Three-dimensional trabecular bone architecture of the lumbar spine in bone metastasis from prostate cancer: comparison with degenerative sclerosis.

Authors:  Tsutomu Tamada; Teruki Sone; Yoshimasa Jo; Shigeki Imai; Yasumasa Kajihara; Masao Fukunaga
Journal:  Skeletal Radiol       Date:  2004-11-16       Impact factor: 2.199

2.  Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer.

Authors:  I Elomaa; T Kylmälä; T Tammela; J Viitanen; J Ottelin; M Ruutu; K Jauhiainen; M Ala-Opas; L Roos; J Seppänen
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

Review 3.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.